Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.

Published in:

2016

By:

• Meulendijks, Didier;
• de Groot, Jan Willem B.;
• Los, Maartje;
• Boers, James E.;
• Beerepoot, Laurens V.;
• Polee, Marco B.;
• Beeker, Aart;
• Portielje, Johanna E.A.;
• Goey, Swan H.;
• de Jong, Robert S.;
• Vanhoutvin, Steven A.L.W.;
• Kuiper, Maria;
• Sikorska, Karolina;
• Pluim, Dick;
• Beijnen, Jos H.;
• Schellens, Jan H.M.;
• Grootscholten, Cecile;
• Tesselaar, Margot E.T.;
• Cats, Annemieke

Publication type:

journal article